Anne Bruinvels joins EPEMED as executive director

Targeted with growing start-up organisation and building its strategic framework

The European Personalised Medicine Diagnostics Association (EPEMED) has appointed Anne Bruinvels, an entrepreneur in personalised healthcare, as executive director and board member.

Bruinvels will be responsible for growing the start-up organisation and, together with the board of directors, for building its strategic framework in creating guidance for all those involved in progressing personalised medicine with an emphasis on European market challenges.

‘I'm delighted to join EPEMED's board and to lead the association to facilitate the development and introduction of personalised medicine in Europe. I'm looking forward to working with the different parties worldwide involved in making real progress in this field,’ said Bruinvels.

Bruinvels started her work in personalised medicine more than 10 years ago. She previously founded Elixior, a personalised healthcare advisory company and prior to that Curidium, a personalised medicine company identifying companion diagnostics and therapeutics to treat patients with central nervous system disorders. She was Curidium's ceo for more than six years and raised several rounds of funding before taking the company public on the AIM of the London Stock Exchange.

Bruinvels has also worked in research for various pharmaceutical companies, including SmithKline Beecham, Wyeth and Sandoz Pharma.

You may also like

Research & Development

DBV Technologies announces last patient visit completed in Phase III peanut allergy trial in children

The Phase III VITESSE clinical trial of the VIASKIN Peanut patch in peanut allergic children aged 4-7 years remains on track for topline data in Q4 of this year
Research & Development

Medicines Discovery Catapult announces collaboration with £15.9m project on next-gen human disease modelling

The Medical Research Council, Wellcome Trust and Innovate UK will work with MDC to develop advanced, specific and highly reproducible human-based in vitro models of disease, with the aim of making them widely available to researchers in academia and industry
Pharma 5.0

Pure Global’s AI Builder cuts MedTech regulatory submission time from weeks to days

New AI platform cuts documentation time by up to 75%, enabling MedTech companies to access 10 times more markets, 10 times faster and 10 times more affordably
Contamination Control

AES Cleanroom Technology opens new regional office in Research Triangle Park

The new office strengthens AES’s presence within North Carolina’s innovation corridor and enhances its ability to give local support to modular cleanroom projects
Regulatory

Nanoform granted European Commercial cGMP Manufacturing Licence for APIs

The Finnish company is now authorised to manufacture nanoformed APIs for the European market and for countries in the Middle East and North Africa, Asia and the Americas, where mutual recognition applies to the European license
Research & Development

Patient dies in CRISPR gene therapy trial

The FDA has now placed Intellia Therapeutics' Phase III CRISPR trials on hold over raised liver enzymes
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Toll processing: a strategic formula for smooth delivery in pharma

Challenged by raw material shortages, compliance demands and capacity limitations, pharmaceutical manufacturers can sometimes struggle to fulfil orders. Ben Beattie, Director of Forbeats, examines the benefits of partnering with a toll processor and the key factors to consider when selecting a provider
Subscribe now